MY136406A - High drug load tablet - Google Patents

High drug load tablet

Info

Publication number
MY136406A
MY136406A MYPI20031513A MY136406A MY 136406 A MY136406 A MY 136406A MY PI20031513 A MYPI20031513 A MY PI20031513A MY 136406 A MY136406 A MY 136406A
Authority
MY
Malaysia
Prior art keywords
drug load
high drug
tablet
load tablet
active
Prior art date
Application number
Other languages
English (en)
Inventor
Christian-Peter Luftensteiner
Jean-Claude Bianchi
Jorg Ogorka
Oskar Kalb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY136406(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY136406A publication Critical patent/MY136406A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20031513 2002-04-23 2003-04-22 High drug load tablet MY136406A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0209265A GB0209265D0 (en) 2002-04-23 2002-04-23 Organic compounds

Publications (1)

Publication Number Publication Date
MY136406A true MY136406A (en) 2008-09-30

Family

ID=9935351

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20031513 MY136406A (en) 2002-04-23 2003-04-22 High drug load tablet

Country Status (31)

Country Link
US (6) US20050267125A1 (de)
EP (1) EP1501485B1 (de)
JP (4) JP2005529126A (de)
KR (1) KR100728846B1 (de)
CN (2) CN1646103A (de)
AR (3) AR039335A1 (de)
AT (1) ATE374016T1 (de)
AU (1) AU2003229705C1 (de)
BR (1) BR0309528A (de)
CA (1) CA2483199C (de)
CY (1) CY1106996T1 (de)
DE (1) DE60316552T2 (de)
DK (1) DK1501485T3 (de)
ES (1) ES2290457T3 (de)
GB (1) GB0209265D0 (de)
GE (1) GEP20094627B (de)
HR (1) HRP20040996B1 (de)
IL (1) IL164678A (de)
MX (1) MXPA04010496A (de)
MY (1) MY136406A (de)
NO (1) NO341027B1 (de)
NZ (1) NZ536046A (de)
PE (1) PE20031045A1 (de)
PL (1) PL199779B1 (de)
PT (1) PT1501485E (de)
RU (2) RU2363450C2 (de)
SI (1) SI1501485T1 (de)
TN (1) TNSN04213A1 (de)
TW (1) TWI350184B (de)
WO (1) WO2003090720A1 (de)
ZA (1) ZA200408441B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1720853B2 (de) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmazeutische zusammensetzungen der 2-kristallform von imatinib-mesylat zur verwendung bei der behandlung von chronischer myelogener leukämie
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
DK2422783T3 (en) 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition
DE502006005084D1 (de) 2005-08-15 2009-11-26 Siegfried Generics Int Ag Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
CA2662265A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
KR20090065512A (ko) 2006-09-22 2009-06-22 노파르티스 아게 Ａｂｌ 티로신 키나제 억제제에 의해 필라델피아-양성 백혈병의 치료를 최적화시키는 방법
EP1920767A1 (de) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Schmelzverarbeitete Darreichungsform mit Imatinib
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
EA022611B1 (ru) 2008-06-27 2016-02-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Способ лечения плексиформной нейрофибромы
US8697702B2 (en) 2008-12-01 2014-04-15 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
EA029416B1 (ru) * 2010-06-21 2018-03-30 Заклады Фармацеутицне Польфарма Са Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения
WO2011161689A1 (en) * 2010-06-21 2011-12-29 Suven Nishtaa Pharma Pvt Ltd Imatinib mesilate pharmaceutical tablet
WO2012019633A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Pharmaceutical granulate comprising imatinib mesylate
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102552268A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种含有α晶型甲磺酸伊马替尼的药物制剂
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
CN102349874B (zh) * 2011-08-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼组合物及其制备方法
CN102349875A (zh) * 2011-10-11 2012-02-15 浙江华海药业股份有限公司 甲磺酸伊马替尼片的制备方法
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2782560A1 (de) 2011-11-24 2014-10-01 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Kurz vor dem gebrauch rekonstituierte feste dosierungsformen von imatinib
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
SG11201405099UA (en) 2012-02-21 2014-10-30 Ranbaxy Lab Ltd Stable dosage forms of imatinib mesylate
GB201204810D0 (en) 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2872142A1 (de) 2012-07-11 2015-05-20 Novartis AG Verfahren zur behandlung von gastrointestinalen stromatumoren
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
GB201304699D0 (en) 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
KR101520792B1 (ko) * 2013-04-10 2015-05-15 보령제약 주식회사 고부하 이매티닙 정제
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
ES2900829T3 (es) 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
CN104749226A (zh) * 2013-12-25 2015-07-01 辰欣药业股份有限公司 一种用电位滴定法测定甲磺酸伊马替尼含量的方法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3257499A1 (de) 2016-06-17 2017-12-20 Vipharm S.A. Verfahren zur herstellung von imatinib methansulfonat kapseln
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
MX2022000418A (es) 2019-07-15 2022-02-10 Intas Pharmaceuticals Ltd Composicion farmaceutica de imatinib.
AU2021392532B2 (en) * 2020-12-01 2025-04-10 Lg Chem, Ltd. Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH176497A (de) 1934-09-14 1935-04-15 Schmid Ernst Alarmvorrichtung.
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3751277A (en) * 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4639458A (en) 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
EP0277092B1 (de) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
JPS63267731A (ja) * 1987-04-23 1988-11-04 Asahi Chem Ind Co Ltd 錠剤組成物
WO1989000424A1 (en) 1987-07-22 1989-01-26 Leo Pharmaceutical Products B.V. Fusidic acid useful in the treatment of aids
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995010264A1 (en) 1993-10-12 1995-04-20 Tokyo Tanabe Company Limited Tablet containing enteric granules
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ATE236639T1 (de) * 1994-09-22 2003-04-15 Akzo Nobel Nv Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
ES2079327B1 (es) 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5805889A (en) * 1995-10-20 1998-09-08 Sun Microsystems, Inc. System and method for integrating editing and versioning in data repositories
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
NZ330864A (en) 1996-02-29 2001-07-27 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet including a disintegrant and a binder
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
JP3212531B2 (ja) * 1997-03-21 2001-09-25 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース崩壊剤及びその製造方法
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
HUP0004407A3 (en) 1997-11-17 2002-03-28 Smithkline Beecham Corp Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
DE19758100B4 (de) * 1997-12-18 2006-05-04 Lichtwer Pharma Ag Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
NZ507271A (en) 1998-03-06 2003-03-28 Eurand Internat S Fast disintegrating tablets
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
DE69930648T2 (de) * 1998-08-12 2006-12-21 Altana Pharma Ag Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
BR9915208A (pt) 1998-11-10 2001-07-31 Bayer Ag Preparado farmacêutico de moxifloxacina
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
IT1311907B1 (it) 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
HK1044277B (en) 1999-08-03 2014-02-28 Icos Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
BR0016236A (pt) 1999-12-09 2002-12-24 Boots Co Plc Agentes terapêuticos
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
AU3589701A (en) 2000-03-03 2001-09-12 Ranbaxy Laboratories Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
KR20070094673A (ko) 2000-03-22 2007-09-20 파마시아 앤드 업존 캄파니 엘엘씨 옥사졸리디논 배합 정제
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
IL152079A0 (en) 2000-04-12 2003-05-29 Novartis Ag Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
CZ20024180A3 (cs) 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan
JP4698000B2 (ja) 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
US7850993B2 (en) 2001-02-27 2010-12-14 Senju Pharmaceutical Co., Ltd. Drug-releasing system of biodegradable polymer type
AU2003216621A1 (en) * 2002-04-10 2003-10-20 The Government Of The United States The Department Of Veterans Affairs Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR072755A2 (es) 2010-09-22
TNSN04213A1 (en) 2007-03-12
MXPA04010496A (es) 2004-12-13
PL371495A1 (en) 2005-06-27
EP1501485A1 (de) 2005-02-02
AU2003229705B2 (en) 2007-01-25
DE60316552D1 (de) 2007-11-08
PL199779B1 (pl) 2008-10-31
IL164678A (en) 2014-02-27
WO2003090720A1 (en) 2003-11-06
RU2405540C1 (ru) 2010-12-10
DE60316552T2 (de) 2008-07-03
NZ536046A (en) 2007-08-31
AU2003229705C1 (en) 2017-09-07
CY1106996T1 (el) 2012-09-26
US20150209291A1 (en) 2015-07-30
US20160101105A1 (en) 2016-04-14
SI1501485T1 (sl) 2008-08-31
GB0209265D0 (en) 2002-06-05
JP2005529126A (ja) 2005-09-29
US20100203133A1 (en) 2010-08-12
TWI350184B (en) 2011-10-11
TW200404009A (en) 2004-03-16
KR20040101550A (ko) 2004-12-02
GEP20094627B (en) 2009-03-10
AR084101A2 (es) 2013-04-24
KR100728846B1 (ko) 2007-06-14
BR0309528A (pt) 2005-02-15
US20120177737A1 (en) 2012-07-12
US20050267125A1 (en) 2005-12-01
US9011911B2 (en) 2015-04-21
EP1501485B1 (de) 2007-09-26
JP5752107B2 (ja) 2015-07-22
CN1646103A (zh) 2005-07-27
CN101653424A (zh) 2010-02-24
ZA200408441B (en) 2005-08-31
PT1501485E (pt) 2007-12-18
JP2015143250A (ja) 2015-08-06
PE20031045A1 (es) 2004-02-10
AU2003229705A1 (en) 2003-11-10
RU2363450C2 (ru) 2009-08-10
HRP20040996B1 (hr) 2010-11-30
CA2483199A1 (en) 2003-11-06
NO20045072L (no) 2005-01-20
JP2013079271A (ja) 2013-05-02
US20140135340A1 (en) 2014-05-15
CA2483199C (en) 2010-08-17
DK1501485T3 (da) 2007-12-27
HK1073253A1 (en) 2005-09-30
NO341027B1 (no) 2017-08-07
ES2290457T3 (es) 2008-02-16
JP2010031019A (ja) 2010-02-12
HRP20040996A2 (en) 2005-06-30
AR039335A1 (es) 2005-02-16
ATE374016T1 (de) 2007-10-15
IL164678A0 (en) 2005-12-18
JP5798269B2 (ja) 2015-10-21
RU2004134323A (ru) 2005-08-10

Similar Documents

Publication Publication Date Title
MY136406A (en) High drug load tablet
MY140999A (en) Dispersible tablets comprising a benzoic acid derivative
MY144477A (en) Galenic formulations of organic compounds
CR6682A (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorios, autoinmunes y respiratorias
TNSN08173A1 (en) Dispersible tablets comprising deferasirox
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BG104441A (en) Cyclic amine derivatives and their use as drugs
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TW200626558A (en) Indazolone derivatives
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
MD2447F2 (en) Pharmaceutical composition, use thereof and methods of treatment of cephalalgia, migraine, sickness and vomiting
ATE495187T1 (de) Dalda-analoge und ihre verwendung
DE602004011966D1 (en) Heterocyclylverbindungen
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
TNSN06220A1 (en) Benzimidazole derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
MXPA06000363A (es) Forma de dosificacion oral de mesilato de saquinavir.
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
TW200640472A (en) Solid pharmaceutical composition comprising telithromycin
MX2024008180A (es) Una composicion farmaceutica solida.
TW200514778A (en) Haloalkyl-and piperidine-substituted benzimidazole-derivatives